NY-JETBLUE
29.4.2021 19:07:13 CEST | Business Wire | Press release
JetBlue (NASDAQ: JBLU) today announced it has taken delivery of the airline’s first Airbus A321 Long Range (LR) aircraft, with tail N4022J arriving at JetBlue’s home at John F. Kennedy International Airport (JFK) Terminal 5 this afternoon. This A321LR was assembled at the Airbus production facility in Hamburg, Germany and will enable JetBlue to launch its first-ever transatlantic service between the U.S. and London this summer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005942/en/
“The delivery of our new A321LR sets the stage for a new era at JetBlue in which we now have an aircraft allowing us to stretch our wings and become a true global carrier offering flights beyond the Americas for the first time ever,” said Robin Hayes, chief executive officer, JetBlue. “The A321LR platform – offering the range of a wide-body but with the economics of a single-aisle aircraft – is the right size for us and will allow us to effectively compete with our award-winning service and low fares on flights between the U.S. and London. We congratulate Airbus on bringing to life the most exciting and innovative narrow bodied aircraft cabin in the world and JetBlue is honored to be the launch customer for Airspace on the A320 family.”
The A321LR allows JetBlue to tap into new long-haul markets, like London, that were not previously accessible with the airline’s existing fleet. The LR’s range of up to 4,000 nautical miles is made possible by three additional center fuel tanks and the aircraft delivers 30 percent fuel savings and nearly 50 percent reduction in noise footprint compared to previous generations of aircraft. JetBlue converted 13 aircraft in its existing A321 order book to the LR version in April 2019 with the ability to convert more. Additionally, JetBlue has converted another 13 aircraft in its existing order book to the Extra-Long Range – or XLR – version of the A321.
JetBlue is also the global launch partner for the new Airspace by Airbus cabin, bringing long-haul style to the A321 for the first time ever. Airspace brings a series of enhancements, many customized for JetBlue, including:
- Stunning backlit ceiling panels through the entire cabin, which glow with a unique-to-JetBlue pattern.
- Custom LED mood lighting that changes throughout different phases of flight to reduce jetlag technologies.
- The largest overhead bins on a single-aisle aircraft.
- New ergonomic sidewalls creating extra personal space at shoulder level.
- A re-designed welcome area at the front boarding door.
- Refreshed onboard restrooms with antimicrobial surfaces.
The modern elements of Airspace, combined with the customizations by JetBlue, offer customers a boutique-style setting for the airline’s highly anticipated transatlantic service.
“We are honored that JetBlue is our first launch operator for the new Airspace cabin on Airbus Single-Aisle aircraft. We are also confident that the airline’s customers and crew alike will appreciate the outstanding comfort and in-flight transatlantic experience on board these aircraft,” said Christian Scherer, Airbus Chief Commercial Officer.
JetBlue’s A321LR is powered by two Pratt & Whitney GTF engines. The GTF engine, with its revolutionary geared fan technology, is transforming aviation by delivering game-changing economic and environmental performance. The Pratt & Whitney GTF engine also incorporates advances in aerodynamics, lightweight materials and other major technology improvements.
“Today we celebrate another exciting and historical milestone between Pratt & Whitney and JetBlue,” said Carroll Lane, president of Commercial Engines at Pratt & Whitney. “The GTF-powered Airbus A321LR aircraft will allow JetBlue to fly farther, opening new routes for their customers, while delivering the economic and environmental benefits of our game-changing engine. We look forward to continuing to power their fleet for decades to come.”
Known in the U.S. for having the most legroom in coach (a), live television and on-demand entertainment on every seatback, free Fly-Fi broadband internet (b), complimentary snacks and soft drinks, and great customer service, JetBlue’s entrance into the transatlantic market will introduce a new era of customer-focused, low-fare travel for leisure and business travelers.
The airline’s Mint® premium experience – which first disrupted transcontinental travel in the U.S. and has been completely reimagined for transatlantic flying – promises to offer customers a fresh choice when flying between the U.S. and the U.K. JetBlue Mint features 24 fully lie-flat private suites with a sliding door, a custom-designed seat cushion by Tuft & Needle, and countless design touches that help every customer feel at home in the air. As part of the refresh, JetBlue will also introduce its latest innovation, the stunning Mint Studio™, which will offer the most space in a premium experience from any U.S. airline (c).
JetBlue’s industry-leading core experience has also been reinvented for crossing the pond and will offer a new level of service to customers who want a great experience at a low fare. All of the comforts JetBlue customers have come to expect will be enhanced by the recently announced partnership with Dig to bring its signature build-your-own dining concept to tray tables at 35,000 feet – JetBlue’s first complimentary meal in core. With just 114 core seats, core customers will enjoy a boutique-style experience no matter where they sit.
Customers in both core and Mint will be able to stay connected throughout the flight with the airline’s popular unlimited, free high-speed Wi-Fi. In addition, customers will have access to a curated selection of live TV channels focused on news and sports, and an extensive library of seatback entertainment – allowing customers to have a multiple screen experience onboard, just like they do at home.
Additional details about specific London routes, schedules and out-for-sale dates will be announced soon.
For the latest JetBlue London news visit: https://www.jetblue.com/flying-with-us/london
For more on the JetBlue’s A321LR aircraft visit: https://www.jetblue.com/flying-with-us/our-planes/A321-long-range
About JetBlue Airways
JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue carries customers across the U.S., Caribbean and Latin America. For more information, visit jetblue.com .
(a)
|
JetBlue offers the most legroom in coach based on average fleet-wide seat pitch for U.S. airlines. |
|
|
|
|
(b)
|
Fly-Fi® and live television are available on all JetBlue-operated flights. Availability and coverage area may vary by aircraft. Details on inflight Wi-Fi and entertainment: |
|
|
|
|
(c) |
Based on personal square footage per passenger seat. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
